|
|
|
| home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace |
|
|
 WHITE PAPERS |
|
Medpace
|
|
The Promise and Challenge of Adaptive Design in Oncology Trials
|
|
Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities
Quanticate, a data-focused clinical research organisation (CRO), has announced that it has partnered with CluePoints as part of its new Data Quality Oversight service.
More info >> |
|
 |
White Papers |
 |
|
Utilising Big Data to Produce Faster and Cheaper Clinical Research
Medical Research Network (MRN) Limited
Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >> |
|
 |
Industry Events |
 |
Cell Therapy Manufacturing & Gene Therapy Congress
4-6 December 2018, RAI, Amsterdam
Bringing together 300+ leaders and key influencers from
pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy
Manufacturing & Gene Therapy will provide you with the latest advice for
transforming innovative research to prosperous cell & gene therapy
manufacturing.
More info >> |
|
|
|
